v3.25.2
FAIR VALUE MEASUREMENTS (Tables)
 6 Months Ended
Jun. 28, 2025
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets Measured on Recurring and Nonrecurring Basis
The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):
June 28, 2025December 31, 2024
Measured at fair value on a recurring basis:Level 1Level 2Level 3Level 1Level 2Level 3
Assets:
Foreign currency forward contracts$— $7.0 $— $— $5.5 $— 
Cross-currency swaps— — — — 14.2 — 
Interest rate swap agreements— 3.5 — — 9.3 — 
Total assets$— $10.5 $— $— $29.0 $— 
Liabilities:
Foreign currency forward contracts$— $5.8 $— $— $5.6 $— 
Cross-currency swaps— 273.5 — — 46.8 — 
Interest rate swap agreements— 34.3 — — 22.6 — 
Total liabilities$— $313.6 $— $— $75.0 $— 
Measured at fair value on a non-recurring basis:
Assets:
Contingent consideration(1)
$— $— $— $— $— $34.5 
Definite-lived intangible assets(2)
— — 5.5 — — 8.2 
Total assets$— $— $5.5 $— $— $42.7 
(1) During the year ended December 31, 2024, contingent consideration was recognized as a result of the divestiture of the Rare Diseases Business.
(2) During the three months ended June 28, 2025, we assessed the fair value of our Prevacid® branded product at $5.5 million, resulting in an asset impairment charge of $1.5 million. During the three months ended December 31, 2024, we assessed the fair value of our Prevacid® branded product at $8.2 million, resulting in an asset impairment charge of $38.6 million.
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments
Our fixed rate long-term debt consisted of the following (in millions):
June 28, 2025December 31, 2024
Public BondsLevel 1Level 1
Carrying value (excluding discount)$2,269.6 $2,221.8 
Fair value$2,200.0 $2,083.9